Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1261P is a processed pseudogene derived from the highly conserved U6 small nuclear RNA gene. U6 snRNA is a fundamental component of the spliceosome, the complex responsible for splicing pre-mRNA in eukaryotes[3][1]. However, RNU6-1261P and similar U6 pseudogenes are "dead-ends": they do not produce functional RNA and are the result of genomic retrotransposition or duplication events[7][5]. Although thousands of such pseudogenes exist in mammalian genomes, including humans, they serve largely as molecular fossils or evolutionary markers[7], not as participants in biological pathways or drug targets. Their structure often closely resembles the original U6 snRNA gene, possibly with partial sequence conservation, but they lack the necessary context or modifications for cellular activity and are not transcribed into functional snRNA[7][5]. Pseudogenes like RNU6-1261P often arise from retrotransposition, where an RNA molecule is reverse-transcribed and inserted back into the genome[7]. U6 snRNA itself is one of the most conserved and functionally critical snRNAs, but pseudogenes derived from U6 have no known regulatory or functional role[1][3][7]. U6 snRNA pseudogenes are sometimes used as phylogenetic or evolutionary markers to trace retrotransposition activity in lineages, but they are not currently described as having biological or disease-associated relevance[7]. No drugs, mechanisms of action, biomarker utility, or safety issues are associated with pseudogenes of this class. RNU6-1261P is a U6 small nuclear RNA pseudogene with no direct biological or pharmaceutical relevance. It is not a therapeutic target, and its inclusion in target databases may be due to automated gene annotation rather than functional evidence.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1261, pseudogene (RNU6-1261P).